EuroPCR 2020 | Sudden Death Increase Two to Three Times While MI Rate Falls

The number of sudden deaths reported around the world is on the rise in Covid-19 times. These deaths are caused either by the virus and its capacity to produce lethal arrhythmias or by the fact that patients are staying away from hospitals and are not being examined. 

Cardiologists were the first to warn that the sudden drop in ACS cases would have negative consequences in the short term, such as late presentation with already deteriorated ventricular function, increased mechanical complications, and increased sudden death. 

The Italian have reported a 58% increase in sudden death at home during Covid peak in the Lombardy region vs. the same period last year. 

Recently, Italian authors have also presented in the European Heart Journal and the virtual EuroPCR a 52% increase in sudden death out of hospital. 

But this time the curve of sudden death out of hospital every 100,000 inhabitants show strong statistic correlation with Covid-19 patients every 100,000 inhabitants.


Read also: EuroPCR 2020 | Is Renal Denervation Coming Back to Life?


Simultaneously, French authors have provided similar information (published in The Lancet): the incidence of sudden death has doubled, and it matches the peak of Covid-19.

In New York (another great epicenter) the same story repeats. After a study published in JAMA, the number of calls to the emergency room for sudden deaths tripled (47.5 vs 15.9 every 100,000 inhabitants) during the peak. The ER was not able to save many of them and mortality went over 90%.

The discussion now revolves around the question of whether these MI patients died because they would not see a doctor in time or because of Covid-19 infection. In New York there are no data on the deceased, but in Paris, approximately one third of the cohort was either confirmed or suspected of infection. 


Read also: Anesthetic Modes and Their Impact on Elective Endoprostheses.


Wildly speculating, we could say up to 70% of sudden death cases in 2020 vs. the same period in 2019 could have been caused by Covid-19, driven by respiratory failure, myocardial injury or pulmonary embolism or prolonged QT (be it inflammatory or drug induced, such as hydroxychloroquine). 

The rest might also have been caused by Covid-19, but only indirectly. This is the case of CAD patients with clear symptoms that would not see a doctor because of fear of catching the disease. 

muerte-subita-extrahospitalaria-ehj muerte-subita-extrahospitalaria-JAMA muerte-subita-extrahospitalaria-Lancet

Original Title: COVID-19 kills at home: the close relationship between the epidemic and the increase of out-of-hospital cardiac arrests. Out-of-hospital cardiac arrest during the COVID-19 pandemic in Paris, France: a population-based, observational study. Out-of-Hospital Cardiac Arrests and Resuscitations During the Novel Coronavirus Disease 2019 Pandemic in New York City.

Reference: Baldi E et al. Eur Heart J. 2020; Epub ahead of print. Marijon E et al. Lancet Public Health. 2020; Epub ahead of print. Lai PH et al. JAMA Cardiol. 2020; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

Rotational atherectomy and its technical secrets: use of floppy or ES guidewire

Rotational atherectomy (RA) remains a very useful tool in the management of severe coronary calcification. However, many of its technical aspects rely more on...

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

Coronary revascularization before TAVI: prior PCI or conservative management?

The coexistence of coronary artery disease (CAD) in patients with severe aortic stenosis undergoing TAVI is common, with a reported prevalence ranging from 30%...

Rotational atherectomy and its technical secrets: use of floppy or ES guidewire

Rotational atherectomy (RA) remains a very useful tool in the management of severe coronary calcification. However, many of its technical aspects rely more on...